BR112015005489A2 - composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas - Google Patents
composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadasInfo
- Publication number
- BR112015005489A2 BR112015005489A2 BR112015005489A BR112015005489A BR112015005489A2 BR 112015005489 A2 BR112015005489 A2 BR 112015005489A2 BR 112015005489 A BR112015005489 A BR 112015005489A BR 112015005489 A BR112015005489 A BR 112015005489A BR 112015005489 A2 BR112015005489 A2 BR 112015005489A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- oral administration
- acid
- absorption
- improved dissolution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
resumo patente de invenção: "composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas". a presente invenção refere-se a uma composição farmacêutica para administração oral que compreende 4-((1-metilpirrol-2-il)-carbonil)-n-(4-(4-morfolin-1-il-carbonilpiperidin-1-il)-fenil)-1-piperazinocar-boxamida, seu sal ou seu solvato, como um ingrediente ativo; e pelo menos um aditivo ácido selecionado do grupo que consiste em ácido adípico, ácido succínico, ácido fumárico, ácido l-aspártico e ácido l-glutâmico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012205681 | 2012-09-19 | ||
| JP2012-205681 | 2012-09-19 | ||
| PCT/JP2013/075157 WO2014046129A1 (ja) | 2012-09-19 | 2013-09-18 | 溶出性及び／又は吸収性が改善された経口投与用医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015005489A2 true BR112015005489A2 (pt) | 2017-07-04 |
| BR112015005489B1 BR112015005489B1 (pt) | 2022-07-12 |
Family
ID=50341439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015005489-7A BR112015005489B1 (pt) | 2012-09-19 | 2013-09-18 | Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9555115B2 (pt) |
| EP (1) | EP2898886B1 (pt) |
| JP (1) | JP5791817B2 (pt) |
| KR (1) | KR101609105B1 (pt) |
| CN (1) | CN104640547B (pt) |
| AU (1) | AU2013319118B2 (pt) |
| BR (1) | BR112015005489B1 (pt) |
| CA (1) | CA2884731C (pt) |
| DK (1) | DK2898886T3 (pt) |
| ES (1) | ES2622585T3 (pt) |
| HK (1) | HK1207969A1 (pt) |
| HU (1) | HUE032635T2 (pt) |
| MX (1) | MX345435B (pt) |
| MY (1) | MY183976A (pt) |
| PL (1) | PL2898886T3 (pt) |
| PT (1) | PT2898886T (pt) |
| RU (1) | RU2589701C1 (pt) |
| SG (1) | SG11201501043TA (pt) |
| TW (1) | TWI536992B (pt) |
| WO (1) | WO2014046129A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707851B (zh) * | 2015-09-17 | 2020-10-21 | 日商大鵬藥品工業股份有限公司 | 哌嗪化合物的新穎結晶 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| JP4292588B2 (ja) * | 1997-01-31 | 2009-07-08 | 日産化学工業株式会社 | ピリダジノン化合物類の経口製剤 |
| TW482675B (en) | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
| JP3797764B2 (ja) * | 1997-10-01 | 2006-07-19 | エーザイ株式会社 | 光安定化組成物 |
| KR100947185B1 (ko) * | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
| EP1397160A1 (en) | 2001-04-30 | 2004-03-17 | Shire Laboratories Inc. | Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| JP2003252762A (ja) * | 2001-12-25 | 2003-09-10 | Takeda Chem Ind Ltd | 酸配合製剤 |
| AU2002357506A1 (en) | 2001-12-25 | 2003-07-15 | Takeda Chemical Industries, Ltd. | Acid-containing preparations |
| DE10209982A1 (de) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
| DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| JP4572293B2 (ja) * | 2004-07-21 | 2010-11-04 | トーアエイヨー株式会社 | ピモベンダン経口投与製剤 |
| MX2009002166A (es) * | 2006-08-31 | 2009-03-12 | Eurand Inc | Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. |
| CL2008000868A1 (es) | 2007-03-28 | 2008-10-10 | Takeda Pharmaceutical | Composicion farmaceutica solida que comprende un compuesto derivado de benzimidazol y un agente de control de ph; metodo de estabilizacion y de mejoramiento de la disolucion; uso de un agente de control de ph. |
| WO2008143240A1 (ja) | 2007-05-21 | 2008-11-27 | Toray Industries, Inc. | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 |
| EP2313096A1 (en) * | 2008-06-04 | 2011-04-27 | AstraZeneca AB (Publ) | New compounds v |
| EP2309985B1 (en) * | 2008-07-28 | 2018-03-14 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| JP5196004B2 (ja) | 2009-03-06 | 2013-05-15 | トヨタ自動車株式会社 | 運転支援装置 |
| CA2754613C (en) | 2009-03-09 | 2016-07-12 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound capable of inhibiting prostaglandin d synthase |
-
2013
- 2013-09-18 SG SG11201501043TA patent/SG11201501043TA/en unknown
- 2013-09-18 KR KR1020157009713A patent/KR101609105B1/ko active IP Right Grant
- 2013-09-18 JP JP2014536878A patent/JP5791817B2/ja active Active
- 2013-09-18 TW TW102133892A patent/TWI536992B/zh active
- 2013-09-18 WO PCT/JP2013/075157 patent/WO2014046129A1/ja active Application Filing
- 2013-09-18 RU RU2015114567/15A patent/RU2589701C1/ru active
- 2013-09-18 BR BR112015005489-7A patent/BR112015005489B1/pt active IP Right Grant
- 2013-09-18 US US14/423,750 patent/US9555115B2/en active Active
- 2013-09-18 PL PL13839200T patent/PL2898886T3/pl unknown
- 2013-09-18 CN CN201380048719.6A patent/CN104640547B/zh active Active
- 2013-09-18 MX MX2015003410A patent/MX345435B/es active IP Right Grant
- 2013-09-18 PT PT138392006T patent/PT2898886T/pt unknown
- 2013-09-18 EP EP13839200.6A patent/EP2898886B1/en active Active
- 2013-09-18 AU AU2013319118A patent/AU2013319118B2/en active Active
- 2013-09-18 CA CA2884731A patent/CA2884731C/en active Active
- 2013-09-18 DK DK13839200.6T patent/DK2898886T3/en active
- 2013-09-18 HU HUE13839200A patent/HUE032635T2/en unknown
- 2013-09-18 ES ES13839200.6T patent/ES2622585T3/es active Active
- 2013-09-18 MY MYPI2015700813A patent/MY183976A/en unknown
-
2015
- 2015-09-02 HK HK15108589.3A patent/HK1207969A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9555115B2 (en) | 2017-01-31 |
| ES2622585T3 (es) | 2017-07-06 |
| SG11201501043TA (en) | 2015-04-29 |
| JP5791817B2 (ja) | 2015-10-07 |
| CA2884731C (en) | 2016-11-01 |
| RU2589701C1 (ru) | 2016-07-10 |
| US20150297722A1 (en) | 2015-10-22 |
| KR20150056827A (ko) | 2015-05-27 |
| PT2898886T (pt) | 2017-03-23 |
| HUE032635T2 (en) | 2017-10-30 |
| TWI536992B (zh) | 2016-06-11 |
| AU2013319118B2 (en) | 2016-03-03 |
| JPWO2014046129A1 (ja) | 2016-08-18 |
| CN104640547A (zh) | 2015-05-20 |
| TW201414476A (zh) | 2014-04-16 |
| CA2884731A1 (en) | 2014-03-27 |
| MY183976A (en) | 2021-03-17 |
| MX345435B (es) | 2017-01-30 |
| MX2015003410A (es) | 2015-06-04 |
| CN104640547B (zh) | 2017-07-11 |
| PL2898886T3 (pl) | 2017-06-30 |
| WO2014046129A1 (ja) | 2014-03-27 |
| EP2898886A1 (en) | 2015-07-29 |
| KR101609105B1 (ko) | 2016-04-04 |
| AU2013319118A1 (en) | 2015-03-12 |
| EP2898886B1 (en) | 2017-02-15 |
| EP2898886A4 (en) | 2016-04-27 |
| HK1207969A1 (en) | 2016-02-19 |
| BR112015005489B1 (pt) | 2022-07-12 |
| DK2898886T3 (en) | 2017-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| TR201904614T4 (tr) | Novel pyrazole derivative. | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| BR112014019667A2 (pt) | formulação de anticorpo abeta | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| BR112015020008A2 (pt) | compostos de biaril amida como inibidores de cinase | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
| BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
| BR112014027359A2 (pt) | moduladores da série de reação complementar e usos dos mesmos | |
| BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112013022213A2 (pt) | administração parenteral de tapentadol | |
| UY31125A1 (es) | Formas amorfas estabilizadas de mesilato de imatinib | |
| CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
| EA201792071A2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| EA201491937A1 (ru) | Инъецируемая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2013, OBSERVADAS AS CONDICOES LEGAIS |